Short description:
AAV capsid Gene Therapy
Drug notes:
13+ additional undisclosed programs RD ALS, Friedreich's ataxia, Parkinson's, rare neurological disease, CNS diseases, undisclosed
Long description:
Voyager Therapeutics is advancing delivery modalities for gene therapies. Many gene therapies are in development, yet delivery of the therapy is still a major limitation. AAVs are a popular choice but require high doses and have off-target effects. Voyager is using its TRACER screening platform to enhance AAV capsids’ specificity and ability to target desired cells and tissues. Voyager’s AAVs also pass the blood-brain barrier, offering the potential to cure neurological diseases. Initial non-human primate data demonstrate the selectivity of TRACER-derived capsids to target the CNS and cardiac muscle. These capsids may enable single-dose treatment for a broad spectrum of diseases.
Jobs:
Associate Director, Chief of Staff (Office of the ... Lexington, MA|8 days ago
Director, IT Infrastructure Lexington, MA|22 days ago
Associate Director, Portfolio Operations Lexington, MA|26 days ago
Research/Senior Research Associate, Non-Viral Deli... Lexington, MA|29 days ago
Senior Director, Antibody Discovery Lexington, MA|29 days ago
Associate Director, Neuroscience Lexington, MA|57 days ago
Director/Senior Director, Chemical Biology Lexington, MA|61 days ago
Sr. Director, Program Lead Lexington, MA|98 days ago
Director, Senior Director Genome Engineering (Vect... Cambridge, MA|100+ days ago